EP2772530B1 - Cell culture assay - Google Patents

Cell culture assay Download PDF

Info

Publication number
EP2772530B1
EP2772530B1 EP12842801.8A EP12842801A EP2772530B1 EP 2772530 B1 EP2772530 B1 EP 2772530B1 EP 12842801 A EP12842801 A EP 12842801A EP 2772530 B1 EP2772530 B1 EP 2772530B1
Authority
EP
European Patent Office
Prior art keywords
scaffold
channel
cell culture
culture assay
leak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12842801.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2772530A4 (en
EP2772530A1 (en
Inventor
Seok Chung
Se Woon HAN
Yoo Jin Shin
Jae Young Byun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea University Research and Business Foundation
Original Assignee
Korea University Research and Business Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea University Research and Business Foundation filed Critical Korea University Research and Business Foundation
Publication of EP2772530A1 publication Critical patent/EP2772530A1/en
Publication of EP2772530A4 publication Critical patent/EP2772530A4/en
Application granted granted Critical
Publication of EP2772530B1 publication Critical patent/EP2772530B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/34—Measuring or testing with condition measuring or sensing means, e.g. colony counters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C12M23/16—Microfluidic devices; Capillary tubes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/34—Internal compartments or partitions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/14—Scaffolds; Matrices
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
    • C12M41/36—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of biomass, e.g. colony counters or by turbidity measurements
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/46—Means for regulation, monitoring, measurement or control, e.g. flow regulation of cellular or enzymatic activity or functionality, e.g. cell viability
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502707—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the manufacture of the container or its components

Definitions

  • the present invention relates to a cell culture assay, and more particularly, to a cell culture assay having a structure which can easily and massively produce cells and more accurately observe a process of culturing cells.
  • Cell migration means migration of living organisms or individual cells in response of various physical, chemical, and biological stimuli, and is deeply involved with various diseases and biological phenomena in a human body, such as AIDS, pathogenic and bacterial infections, arteriosclerosis, arthritis, periodontitis, psoriasis, cancer, multiple sclerosis, male infertility, asbestos poisoning, ozone poisoning, etc.
  • the microfluidic technology can provide microenvironments around a cell, allow real-time observation and accurate quantification of a reaction of cells, reduce an amount of cells or samples used in a test, and evaluate various test conditions.
  • a scaffold-integrating technique can three-dimensionally introduce cells, culture cells in various directions, such as inside and both sides of a scaffold. Therefore, various cells can be cultured at the same time, and thereby interaction of the cells and interaction between the cells and the scaffolds can be studied. For this reason, the scaffold-integrating technique can also be applied in development of medical materials. Moreover, effects of various materials including a nanomaterial, a drug, and a protein on cells may be three-dimensionally evaluated.
  • a microfluidic platform according to a conventional art needs a pole array having a size of several tens to several hundreds of micrometers to fix between scaffold channels. If there is no pole, scaffolds may be leaked into the channels, and therefore the conventional microfluidic platform cannot be applied.
  • most scaffolds are present in a liquid type. They are solidified after being injected into a specific location in a channel, and therefore a pole is needed to block the injected scaffolds in the specific location before they are solidified.
  • the above-described microfluidic platform has a limit to an area in which cells are reacted due to the pole preventing leakage of the scaffolds, and is very difficult to massively produce cells.
  • the pole is still seen during observation, which becomes a factor disturbing quantification, and the critical problem is that the cells are preferentially reacted with the pole rather than the scaffolds.
  • the present invention is directed to providing a cell culture assay having a structure not allowing cells to be preferentially reacted with scaffolds, and enabling to be fixed between scaffold channels at the same time.
  • One aspect of the present invention provides a cell culture assay, which includes a substrate; a scaffold channel which is formed along the center inside the substrate, at least one of which is formed continuously, and inside which a scaffold flows; and a microfluidic channel which is formed on one side or on both sides of the scaffold channel, and inside which cells flow.
  • a cell culture assay which includes a substrate; a scaffold channel which is formed along the center inside the substrate, at least one of which is formed continuously, and inside which a scaffold flows; and a microfluidic channel which is formed on one side or on both sides of the scaffold channel, and inside which cells flow.
  • At least one of the ceiling surface and the floor surface of a boundary part of the microfluidic channel and the scaffold channel includes a leak-preventing part for preventing the scaffold from leaking into the microfluidic channel.
  • the microfluidic channel and the scaffold channel have semicircular upper parts, and the semicircular upper parts are in contact with each other so that the leak-preventing part is formed at the boundary part therebetween.
  • the leak-preventing part has a cross section which has a sharp tip and both sides of which are curved.
  • the leak-preventing part is formed to have a rounded tip.
  • the leak-preventing part is formed to have a tip having a square cross section.
  • the leak-preventing part is formed to account for 5% to 95% of the height of the scaffold channel and the microfluidic channel.
  • the scaffold channel and the microfluidic channel are alternately and repeatedly disposed.
  • Both ends of the microfluidic channel extend in a direction being distant from the scaffold channel.
  • a leak-preventing part extends to a ceiling surface or a floor surface of a boundary part of a scaffold channel and a microfluidic channel, cells are prevented from reacting first with other structures, thereby enabling accurate quantification in observation of cell culture and a reaction of cells and interaction of cells to be studied.
  • a test time may be reduced by simultaneously observing various cells.
  • FIG. 1 is a plan view of a cell culture assay according to one embodiment of the present invention
  • FIG. 2 is a cross-sectional view taken along line I-I of FIG. 1 .
  • a scaffold channel 20 and a microfluidic channel 30 are each formed on a rectangular substrate 10.
  • the substrate 10 may be formed of a material that can realize a microfluidic structure in which a very small amount of any material can be transferred.
  • microfluidic channels 30 in which cells flow are disposed at both sides of the substrate 10, and the scaffold channel 20 is disposed between the microfluidic channels 30.
  • a plurality of scaffold channels 20 may be sequentially disposed between the microfluidic channels 30.
  • the scaffold channels 20 are disposed in a straight line across the center of the substrate 10.
  • a scaffold inlet 22 is formed in a front end (upstream) of the scaffold channel 20, and a scaffold outlet 24 is formed in a rear end (downstream) thereof.
  • microfluid inlet and outlet 32 and 34 are respectively formed in front and rear ends of the microfluidic channel 30.
  • scaffolds 50 in the scaffold channel 20, scaffolds 50 (refer to FIG. 3A ) flow, and due to the scaffolds 50 constituting an extracellular matrix (ECM), all of advantages of the microfluidic technology are maintained and a three-dimensional reaction of cells in evaluation of the cell flow may be simulated.
  • Such scaffolds 50 must flow inside the scaffold channel 20 and must not leak into the microfluidic channel 30.
  • the scaffolds 50 are a liquid type, and thus are solidified after being injected into a specific location in the scaffold channel 20.
  • the scaffolds 50 may be formed of a material which becomes solidified or gelated, cured, sticky, or is formed into a pipe form, after being injected in a fluid type.
  • a method of applying heat, chemically mixing, taking predetermined time, or irradiating light (particularly, UV rays) may be used.
  • the solidified or gelated scaffolds 50 may be formed of alginate, collagen, a peptide, fibrin, hyaluronic acid, agarose, or PEG, and alternatively, a hydrogel, a general gel, an agarose gel, a tissue, a protein, or an actual matrix material may be used.
  • the scaffolds 50 may be formed of a material directly extracted from a living body, for example, cells, a cell cluster, or living tissues, or a mixture thereof.
  • both ends of the scaffold channel may have an inwardly depressed shape, and as time passes, the scaffolds 50 are scattered to both sides, as shown in FIG. 3B , they have a protruding shape.
  • the shape may depend on a surface contact angle of the channel, and may be manipulated in a specific shape. According to the above-described process, the scaffolds 50 may be prevented from leaking into the microfluidic channel 30 due to surface tension with the leak-preventing part 40.
  • the leak-preventing part 40 may be formed on a ceiling surface or floor surface of the boundary part of the scaffold channel 20 and the microfluidic channel 30, and in FIG. 2 , it is shown that the leak-preventing part 40 is formed on the ceiling surface.
  • the leak-preventing part 40 has a cross section which has a sharp tip and both sides of which are curved. This shape may be realized by forming upper parts of the scaffold channel 20 and the microfluidic channel 30 in a semicircular shape, and disposing the semicircular parts in contact with each other.
  • the leak-preventing part 40 may be formed to have a square cross section.
  • the above-described leak-preventing part 40 extends to a predetermined length on the ceiling surface or the floor surface of the boundary part of the scaffold channel 20 and the microfluidic channel 30, but a shape of the leak-preventing part 40 is not particularly limited.
  • the leak-preventing part 40 may be formed to account for 5% to 95% of the height of the scaffold channel 20 and the microfluidic channel 30.
  • the leak-preventing part 40 may be formed to account for less than 5% of the height of the scaffold channel 20 and the microfluidic channel 30, capillarity may be difficult to be maintained, and when the leak-preventing part 40 is formed to account for more than 95%, a drug/molecule may not be actively migrated.
  • the leak-preventing part 40 may be formed to account for various ranges, for example, 20% to 80%, 30% to 70%, or 40% to 60% of the height of the scaffold channel 20 and the microfluidic channel 30.
  • both ends of the microfluidic channel 30 extend in a direction being distant from the scaffold channel 20 or in various methods. Accordingly, the scaffolds 50 substantially meet the fluid between the upstream and the downstream.
  • cells may be cultured in various directions such as inside and both sides of the scaffold channel 20, and various cells can be cultured at the same time.
  • interaction between cells and interaction between cells and scaffolds can be studied, which can be applied in development of medical materials.
  • FIGS. 6A to 6C are perspective views showing a process of injecting scaffolds to the cell culture assay according to one embodiment of the present invention.
  • the scaffolds 50 are injected into the scaffold inlet 22, and flow along the scaffold channel 20.
  • the scaffold 50 may be fixed on the scaffold channel 20 without leaking into the microfluidic channel 30 due to the leak-preventing part 40 although injected in an amount indicated in FIG. 6C .
  • FIGS. 7A and 7B are perspective views of cross sections of different channel structures of the cell culture assay according to the present invention.
  • the scaffold channel 20 and the microfluidic channel 30 of the cell culture assay may be disposed in various manners.
  • the microfluidic channels 30 are disposed at both sides, and one scaffold channel 20 is disposed therebetween.
  • arrangement of the scaffold channel 20 and the microfluidic channel 30 is not necessarily limited to the above-described embodiment, as shown in FIG. 4 , a plurality of scaffold channels 20 may be sequentially disposed, and as shown in FIG. 5 , the scaffold channel 20 and the microfluidic channel 30 may be alternately and repeatedly disposed. As the scaffold channel 20 and the microfluidic channel 30 are disposed in various ways as described above, various kinds of cell culture may be simultaneously confirmed.
  • FIG. 8 shows culture of vascular endothelial cells through the conventional cell culture assay.
  • vascular endothelial cells are grown along a pole array and a wall in the conventional art. That is, there is a limit to an area in which the cells are reacted, the pole is still shown during observation, which disrupts quantification, and the cells are preferentially reacted with the pole array.
  • parts represented in red are preferably wider to observe interactions between cells, between cells and gels, and by chemical factors. However, to maintain surface tension, the parts in red have a limit to be enlarged.
  • the vascular endothelial cells are stably grown. Therefore, according to the cell culture assay of the present invention, the interactions between cells, between cells and gels and by chemical factors are easily observed, and the substrate is also easily formed.
  • the vascular endothelial cells are used as an example, but it is apparent that the cell culture assay according to the present invention uses various cells including the vascular endothelial cells.
  • the cell culture assay described above is generally used in evaluation of cell migration under various environmental conditions, and can be applied in various uses such as development of new drugs, construction of disease models such as cancers, Alzheimer's, etc., construction of tissues and organ models, simulation of biological environment, toxicity evaluation, drug evaluation, contamination evaluation, protein and other material evaluation, biocompatibility evaluation, stem cell studies, etc.
EP12842801.8A 2011-10-28 2012-10-29 Cell culture assay Active EP2772530B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110111302A KR101322798B1 (ko) 2011-10-28 2011-10-28 세포배양 어세이
PCT/KR2012/008917 WO2013062383A1 (ko) 2011-10-28 2012-10-29 세포배양 어세이

Publications (3)

Publication Number Publication Date
EP2772530A1 EP2772530A1 (en) 2014-09-03
EP2772530A4 EP2772530A4 (en) 2015-07-15
EP2772530B1 true EP2772530B1 (en) 2019-04-03

Family

ID=48168114

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12842801.8A Active EP2772530B1 (en) 2011-10-28 2012-10-29 Cell culture assay

Country Status (5)

Country Link
US (1) US9523672B2 (ko)
EP (1) EP2772530B1 (ko)
JP (2) JP2014530635A (ko)
KR (1) KR101322798B1 (ko)
WO (1) WO2013062383A1 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101322798B1 (ko) * 2011-10-28 2013-10-29 고려대학교 산학협력단 세포배양 어세이
CN105713835B (zh) * 2014-12-05 2018-11-09 中国科学院大连化学物理研究所 一种基于微流控芯片的多功能区域细胞三维共培养方法
KR101896618B1 (ko) * 2015-12-07 2018-09-07 서울대학교산학협력단 세포외소포체 추적 관찰 시스템
KR20170074503A (ko) * 2015-12-22 2017-06-30 고려대학교 산학협력단 세포 배양 어세이를 이용한 약물 평가 방법
US10767149B2 (en) * 2016-06-13 2020-09-08 Massachusetts Institute Of Technology Microfluidic device for three dimensional and compartmentalized coculture of neuronal and muscle cells, with functional force readout
WO2018063099A1 (en) * 2016-09-29 2018-04-05 Nanyang Technological University Three-dimensional (3d) hydrogel patterning in microfluidic vascular models
KR101949612B1 (ko) * 2016-11-29 2019-02-19 고려대학교 산학협력단 미세 유체칩
IT201600131735A1 (it) * 2016-12-28 2018-06-28 Milano Politecnico Costrutti tridimensionali multistrato in microcanali
KR101848201B1 (ko) * 2017-01-04 2018-05-24 고려대학교 산학협력단 조직을 구성하는 이기종 세포 간의 반응 연구를 위한 반응 연구 칩
EP3642352A4 (en) * 2017-06-19 2021-03-24 Curiochips MICROFLUIDIC DEVICE WITH PARTIALLY ENCAPSULATED MICROFLUIDIC CHANNEL AND THE USE OF IT
KR20190088337A (ko) 2018-01-18 2019-07-26 포항공과대학교 산학협력단 나노 섬유 기저 막을 생체 모사 조직 표면에 형성시키는 방법
KR20190088354A (ko) 2018-01-18 2019-07-26 포항공과대학교 산학협력단 세포친화성 물질로 피복된 나노 섬유상 기저 막과 제조 방법
AU2021261373A1 (en) * 2020-04-22 2022-11-17 The Board Of Trustees Of The Leland Stanford Junior University Microfluidic chips and microphysiological systems using the same
WO2023145208A1 (ja) * 2022-01-31 2023-08-03 株式会社エンプラス 流体取扱装置、その製造方法、および流体取扱装置への流動性媒体の導入方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5061408B2 (ja) 2001-05-01 2012-10-31 日産自動車株式会社 固体電解質型燃料電池用スタック及び固体電解質型燃料電池
US6943008B1 (en) * 2002-08-21 2005-09-13 Florida State University Research Foundation, Inc. Bioreactor for cell culture
SG131130A1 (en) * 2004-07-06 2007-04-26 Agency Science Tech & Res Biochip for sorting and lysing biological samples
JP4619728B2 (ja) * 2004-09-02 2011-01-26 株式会社エンプラス 試料分析装置
CA2586400A1 (en) * 2004-11-11 2006-05-18 Agency For Science, Technology And Research Cell culture device
KR100733914B1 (ko) 2005-09-22 2007-07-02 한국과학기술원 미세유체 기술을 이용한 3차원 세포배양 시스템
US8603806B2 (en) 2005-11-02 2013-12-10 The Ohio State Universtiy Research Foundation Materials and methods for cell-based assays
WO2009061392A1 (en) 2007-11-05 2009-05-14 President And Fellows Of Harvard College Forming gel structures using microfluidic channels
CN103635587A (zh) * 2008-04-08 2014-03-12 麻省理工学院 三维微流平台和其使用方法
SG189160A1 (en) * 2010-09-29 2013-05-31 Massachusetts Inst Technology Device for high throughput investigations of cellular interactions
KR101322798B1 (ko) * 2011-10-28 2013-10-29 고려대학교 산학협력단 세포배양 어세이

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP2772530A4 (en) 2015-07-15
EP2772530A1 (en) 2014-09-03
KR20130046750A (ko) 2013-05-08
JP2016146851A (ja) 2016-08-18
JP6457434B2 (ja) 2019-01-23
US9523672B2 (en) 2016-12-20
US20140302594A1 (en) 2014-10-09
KR101322798B1 (ko) 2013-10-29
JP2014530635A (ja) 2014-11-20
WO2013062383A1 (ko) 2013-05-02

Similar Documents

Publication Publication Date Title
EP2772530B1 (en) Cell culture assay
US10012640B2 (en) Cell culture device with an array of microfluidic networks
Sung et al. Microfluidic 3D models of cancer
Sivagnanam et al. Exploring living multicellular organisms, organs, and tissues using microfluidic systems
US11920116B2 (en) Systems and methods for producing micro-engineered models of the human cervix
KR20140113139A (ko) 세포 스페로이드 배양판
US8355876B2 (en) Microfluidic assay for selection and optimization of drug delivery vehicles to tumors
US10744505B2 (en) Microfluidic device for in vitro 3D cell culture experimentation
US10106768B2 (en) Micro cell culturing device
CN115261224A (zh) 细胞培养、运输和探究
US20110244567A1 (en) Device and Method of 3-Dimensionally Generating IN VITRO Blood Vessels
Virumbrales-Muñoz et al. From microfluidics to microphysiological systems: Past, present, and future
KR20150051199A (ko) 세포 스페로이드 배양판
JP6296620B2 (ja) 細胞評価用ハイドロゲル基材、細胞評価用ハイドロゲル基材の作製方法および細胞評価手法
US11781101B2 (en) 3D-printed models of biological microenvironments
JP7413644B2 (ja) バイオウォール、ビーズ床、及びバイオインターフェースを含む細胞を培養するためのマイクロ流体デバイス、並びにマイクロ流体デバイスのバイオインターフェースをモデル化する方法
US9453252B2 (en) Microfluidic assay in idealized microvascular network for selection and optimization of drug delivery vehicles to simulated tumors
CN206512226U (zh) 一种细胞培养装置
KR20200008688A (ko) 3차원 세포 배양 에세이
Janmey et al. Physical sciences and engineering advances in life sciences and oncology
Gong A Multiscale Study Revealing the Interplay between Tumor Growth and the Three-Dimensional Extracellular Matrix
Nguyen et al. Simple and Rapid Method of Microwell Array Fabrication for Drug Testing on 3D Cancer Spheroids
Cai et al. Newly emerged engineering of in vitro 3D tumor models using biomaterials for chemotherapy
Zhang Microfluidic Gradient Device for Studying the Mesothelial Cells' Migration and Effects of Carbon Nanotubes Chronic Exposure

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140514

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150616

RIC1 Information provided on ipc code assigned before grant

Ipc: C12M 1/34 20060101AFI20150610BHEP

Ipc: C12M 1/00 20060101ALI20150610BHEP

Ipc: G01N 33/48 20060101ALI20150610BHEP

Ipc: B01L 3/00 20060101ALI20150610BHEP

Ipc: C12Q 1/02 20060101ALI20150610BHEP

Ipc: C12M 3/00 20060101ALI20150610BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20181018

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1115741

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190415

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012058675

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190403

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1115741

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190803

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190704

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190803

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012058675

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

26N No opposition filed

Effective date: 20200106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191029

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20191029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191029

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20121029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190403

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231005

Year of fee payment: 12